Effect of nafarelin on uterine fibroids measured by ultrasound and magnetic resonance imaging.

Abstract

Administration of the LHRH agonist, Nafarelin (D-(Nal2)6 GnRH), at a dosage of 200 micrograms twice daily intranasally in 13 patients with uterine leiomyomata resulted in a reduction in uterine volume to a mean of 55.1% at 3 months and 44.5% at 6 months as measured using ultrasound. Re-enlargement occurred on discontinuing therapy and the uterus was back to the original volume at three months. Magnetic resonance imaging (MRI) performed in five patients showed advantages over ultrasound in identification of fibroid number in two patients. Mean reduction in uterine area measured using MRI was 61.3%, and mean reduction of fibroid area 57%. Oestradiol was suppressed with treatment to a mean of 69 pmol/l.

• Authors: I A Williams, R W Shaw
• Journal: European journal of obstetrics, gynecology, and reproductive biology (Eur J Obstet Gynecol Reprod Biol) 1990 Jan-Feb Vol. 34 Issue 1-2 Pg. 111-7 ISSN: 0301-2115 [Print] Ireland
• PMID: 2137421 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Nafarelin
• Gonadotropin-Releasing Hormone

Topics

• Administration, Intranasal
• Adult
• Female
• Gonadotropin-Releasing Hormone (administration & dosage, analogs & derivatives, therapeutic use)
• Humans
• Leiomyoma (drug therapy, pathology)
• Magnetic Resonance Imaging
• Nafarelin
• Ultrasonics
• Uterine Neoplasms (drug therapy, pathology)